Nuclear Medicine and Neurooncology (NMN)'s Avatar

Nuclear Medicine and Neurooncology (NMN)

@nmnsymposium.bsky.social

Advancing Nuclear Medicine and Neurooncology through research and education. Join the #NMN2025 Symposium on May 09/10th 2025 in Vienna, Austria. nmn-society.org

170 Followers  |  128 Following  |  96 Posts  |  Joined: 20.12.2024  |  1.9985

Latest posts by nmnsymposium.bsky.social on Bluesky

Post image

πŸ’« Check out the new article in the inaugural issue of the new EANM Journal:
EANM insights on PET-based response assessment in neuro-oncology: things are moving forward!
doi.org/10.1016/j.ea...
@eanm.org

24.09.2025 07:09 β€” πŸ‘ 4    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

We’re thrilled to see so many high-quality submissions coming in for our journals! πŸŽ‰

Explore the latest publications and the editorials written by our EANM Board and Editors-in-Chief:

πŸ‘‰ The EANM Journal: sciencedirect.com/journal/the-...
πŸ‘‰ EANM Innovation: sciencedirect.com/journal/eanm...

24.09.2025 06:41 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data - European Journal of Nuclear Medicine and Molecular Imaging Purpose This study aimed to reveal the factors affecting the therapeutic response of refractory meningiomas treated with [177Lu]Lu-DOTATATE and to collect initial tumor absorbed doses. Methods Patient...

🚨New paper in EJNMMI: [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data.
link.springer.com/article/10.1...

22.09.2025 16:09 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Who’s ready for 2025 WFNOS/SNO Annual meeting in Honolulu?!

Register by Sept 19 to get early bird pricing and join colleagues from around the world in advancing #neurooncology.

soc-neuro-onc.org/SNO2025

05.09.2025 15:38 β€” πŸ‘ 3    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Preview
EANS-EANO Guidelines on the extent of resection in gliomas Abstract. Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence emplo

🧠 EANS-EANO Guidelines on the extent of resection in gliomas.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social @neuroonc.bsky.social

17.09.2025 15:47 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

🚨 πŸ’« Happy to share that that @eortc.org is a πŸ™Œ collaboration partner for the #NMN2026 Symposium: www.nmn-society.org!
@nathaliealbert.bsky.social

13.09.2025 14:08 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. Me...

🚨 New publication in Journal of Nuclear Medicine: Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.
jnm.snmjournals.org/content/earl...

12.09.2025 12:42 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted rad…

🌎 ☒️ 🩺 Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access.
www.sciencedirect.com/science/arti...

11.09.2025 14:55 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
The molecular blueprint of targeted radionuclide therapy - Nature Reviews Clinical Oncology Targeted radionuclide therapy (TRT) is a therapeutic modality that combines the strengths of radiotherapy and systemic molecularly targeted therapy. Over the past few years, new TRT agents have been d...

New publication in Nature Reviews Clinical Oncology: The molecular blueprint of targeted radionuclide therapy.
www.nature.com/articles/s41...

11.09.2025 14:24 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors - European Journal of Nuclear Medicine and Molecular Imaging Purpose Amino acid PET with [18F]-fluoroethylthyrosine ([18F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors ...

Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.
link.springer.com/article/10.1...

10.09.2025 08:24 β€” πŸ‘ 4    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Preview
Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria AbstractBackground. We evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their proficiency in predicting longer survival i

Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria.
academic.oup.com/noa/advance-...

10.09.2025 08:24 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Introduction | Cancer Neuroscience | The European Association for Cancer Research

🚨 Registration deadline for the EACR conference on #cancerneuroscience is September 15 ‼️

Please join us in beautiful Bilbao for exciting discussions on the dialogue between the nervous system and cancer πŸ”¬πŸ§ 

See you soon!

10.09.2025 06:15 β€” πŸ‘ 9    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Preview
Tumor Versus Capillary Telangiectasia in Recurring... : Clinical Nuclear Medicine stant tumor manifestation. However, multimodal MRI revealed a benign capillary telangiectasia in the anterior cingulate gyrus. While 18F-FET-PET is highly sensitive for detecting tumor activity, vascu...

Tumor Versus Capillary Telangiectasia in Recurring Glioblastoma.
journals.lww.com/nuclearmed/f...
@nathaliealbert.bsky.social

09.09.2025 06:32 β€” πŸ‘ 4    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0

Thank you! We're pleased to support the #NMN2026 Symposium and collaborate with colleagues across the global neuro-oncology community. 🌐🧠 #EANO #Collaboration #NeuroOncology

05.09.2025 17:46 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma AbstractBackground. Early after surgery and completion of first-line radiotherapy with concomitant temozolomide, the prediction of progression-free and ove

Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma.
ο»Ώacademic.oup.com/noa/advance-...

05.09.2025 15:36 β€” πŸ‘ 5    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

🀩 Happy to share that the EANO is endorsing the #NMN2026 Symposium: www.nmn-society.org! πŸ’« Excited to join forces with the leading mulitdisciplinary neuro-oncology society in Europe 🌎 !
www.eano.eu
@eanoassociation.bsky.social @nathaliealbert.bsky.social @michael-platten.bsky.social

01.09.2025 10:18 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Preview
Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18Β F]FET-PET/MRI - European Journal of Nuclear Medic... Purpose The isocitrate dehydrogenase (IDH) genotype is crucial for diagnosing and managing adult-type diffuse glioma. We investigated spatial tumour characteristics in treatment-naΓ―ve glioma using an ...

Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.
ο»Ώlink.springer.com/article/10.1...

28.08.2025 12:13 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling - Nature Cancer Vallentgoed et al. integrate clinical and multiomic data from persons with matched initial and recurrent IDH-mutant astrocytomas to identify progression-associated mechanisms and report a DNA methylat...

⭐️New Article published at Nature Cancer!

'Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling'

βœ’οΈBy Wies Vallentgoed and colleagues

πŸ”— www.nature.com/articles/s43...

27.08.2025 10:41 β€” πŸ‘ 7    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
Preview
Convection-enhanced delivery of [225Ac]Ac-DOTA-SP in recurrent glioblastoma – tumour uptake - European Journal of Nuclear Medicine and Molecular Imaging European Journal of Nuclear Medicine and Molecular Imaging -

Convection-enhanced delivery of [225Ac]Ac-DOTA-SP in recurrent glioblastoma – tumour uptake.
link.springer.com/article/10.1...

27.08.2025 08:15 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

πŸ”₯ Hot off the press in Neuro-Oncology by @mj-mair.bsky.social et al: Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET – a retrospective, bicentric cohort study.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social

26.08.2025 12:35 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
Early seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report Vorasidenib, a dual isocitrate dehydrogenase 1/2 (IDH1/2) inhibitor, showed superior efficacy in prolonging progression-free survival and time to next intervention in IDH-mutant grade 2 gliomas. This...

Early seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report.
onlinelibrary.wiley.com/doi/full/10....

25.08.2025 14:07 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
The role of amino acid PET in the era of checkpoint... : Current Opinion in Neurology nt-related changes such as pseudoprogression and pseudoresponse from true tumor relapse in patients receiving immunotherapy or targeted therapies for brain metastases and gliomas, often outperforming ...

The role of amino acid PET in the era of checkpoint inhibitors and targeted therapy for brain tumor treatment.
journals.lww.com/co-neurology...

25.08.2025 08:02 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

🧠 Just published in Neuro-Oncology: A comprehensive consensus review by @neuroonc.bsky.social and EANO on current management and future directions in adult #Glioblastoma care. Explore key recommendations and research priorities.
πŸ”— academic.oup.com/neuro-oncolo...

#NeuroOncology

23.08.2025 08:17 β€” πŸ‘ 10    πŸ” 5    πŸ’¬ 1    πŸ“Œ 0
Preview
The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective Abstract. The Response Assessment in NeuroOncology (RANO) criteria for response to treatment in glioma make a distinction between enhancing and unenhancing

The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social @neuroonc.bsky.social

21.08.2025 16:02 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

Have you read the new edition of our #ICOM newsletter?

In it, you can read about the latest #meningioma-related events and articles from our members.

adobe.ly/45yJe1R

20.08.2025 09:54 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions Abstract. Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021 the World Health Orga

πŸ”₯ Hot of the press in Neuro-Oncology! 🧠 #Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social @neuroonc.bsky.social

19.08.2025 07:33 β€” πŸ‘ 3    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image

🀩 Happy to share that the Asian Society for Neuro-Oncology (ASNO) is endorsing the #NMN2026 Symposium: www.nmn-society.org! 🌎 Looking forward to this collaboration to advance Nuclear Medicine and Neuro-Oncology on a global level!
www.a-sno.org

@nathaliealbert.bsky.social

18.08.2025 11:09 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

πŸ”₯ Hot off the press in JNM: [177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. 🩺 Study enrollment is ongoing.
jnm.snmjournals.org/content/earl...
@nathaliealbert.bsky.social @journalofnucmed.bsky.social @eortc.org

08.08.2025 08:17 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

EANO and @neuroonc.bsky.social welcome @wickwolfgang.bsky.social, MD as the new Editor-in-Chief of Neuro-Oncology Advances! Thanks to @gelarehzadeh.bsky.social for seven years of outstanding leadership. Exciting new chapter ahead!
#NeuroOncology #EANO #SNO #NeuroOncologyAdvances

06.08.2025 19:35 β€” πŸ‘ 8    πŸ” 2    πŸ’¬ 0    πŸ“Œ 1

@nmnsymposium is following 20 prominent accounts